Capula Management Ltd Acquires New Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Capula Management Ltd acquired a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 4th quarter, HoldingsChannel reports. The firm acquired 35,670 shares of the biotechnology company’s stock, valued at approximately $320,000.

Other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in shares of Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 89,940 shares during the last quarter. FMR LLC boosted its stake in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the period. BNP Paribas Financial Markets grew its position in Aurinia Pharmaceuticals by 172.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 20,324 shares during the last quarter. Verition Fund Management LLC grew its position in Aurinia Pharmaceuticals by 209.0% in the 3rd quarter. Verition Fund Management LLC now owns 58,518 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 39,583 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after purchasing an additional 64,949 shares during the period. Institutional investors own 36.83% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Insiders Place Their Bets

In related news, CFO Joseph M. Miller sold 61,859 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares in the company, valued at approximately $5,068,120. This represents a 8.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company’s stock, valued at $1,263,173.32. The trade was a 5.13 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,898 shares of company stock worth $2,753,094. 4.30% of the stock is owned by insiders.

Aurinia Pharmaceuticals Price Performance

NASDAQ AUPH opened at $7.59 on Tuesday. The firm has a market capitalization of $1.04 billion, a PE ratio of -50.60 and a beta of 1.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The company’s 50 day simple moving average is $8.09 and its 200 day simple moving average is $8.09.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.